Tremfya Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tremfya market research report is one of a series of new reports that provides tremfya market statistics, including tremfya industry global market size, regional shares, competitors with a tremfya market share, detailed tremfya market segments, market trends and opportunities, and any further data you may need to thrive in the tremfya industry. This tremfya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing healthcare infrastructure, rising adoption of point-of-care testing, increasing investment in healthcare research, and growing focus on precision medicine. Major trends in the forecast period include advancements in treatment modalities, personalized medicine approaches, technological integration in patient monitoring, integration of artificial intelligence (AI), and advancements in injection devices.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the tremfya market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own cells, tissues, or organs, mistaking them for foreign invaders. This rise in autoimmune conditions can be attributed to factors such as genetic predisposition, environmental triggers, lifestyle changes, greater awareness, and improved diagnostic capabilities. Tremfya, a monoclonal antibody that targets interleukin-23 (IL-23), plays a vital role in managing autoimmune diseases by modulating the immune system's excessive response, reducing inflammation, and alleviating symptoms in conditions such as psoriasis and psoriatic arthritis. For example, a report published by the Australian Institute of Health and Welfare in June 2024 highlighted that in 2022, there were 10,000 hospitalizations due to rheumatoid arthritis, marking a 25% increase from the previous year, with a hospitalization rate of 39 per 100,000 people. This growing prevalence of autoimmune diseases is contributing to the increasing demand for tremfya.

The rise in healthcare expenditure is also expected to stimulate growth in the tremfya market. Healthcare expenditure includes the total spending on medical services, products, and public health initiatives aimed at maintaining and improving health. This increase in spending is driven by an aging population requiring more healthcare services and the rising incidence of chronic conditions such as diabetes and heart disease. Higher healthcare expenditure improves access to advanced biologic therapies such as tremfya by enhancing reimbursement coverage, diagnostic rates, and patient affordability. For instance, according to a report from the American Hospital Association published in December 2022, healthcare spending in the United States reached $4.5 trillion, an increase of 4.1% from the previous year. The continued growth in healthcare expenditure is expected to fuel the market for tremfya.

A significant trend in the tremfya market is the expansion of its approved indications, which increases its market potential. Regulatory approvals, granted by authorities such as the FDA or the European Medicines Agency (EMA), allow a drug to be marketed for new uses after demonstrating its safety, efficacy, and quality. For instance, in September 2024, Johnson & Johnson received FDA approval for tremfya (guselkumab) to treat adults with moderately to severely active ulcerative colitis, marking it as the first dual-acting interleukin-23 inhibitor approved for this condition. This approval was based on positive results from the Phase 2b/3 QUASAR study, which showed that approximately 50% of patients achieved clinical remission after 44 weeks of treatment. Tremfya works by targeting interleukin-23, helping to normalize the inflammatory response in the colon.

The key company operating in the tremfya market is Johnson & Johnson.

North America was the largest region in the tremfy market in 2024. The regions covered in tremfya report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tremfya market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tremfya (guselkumab) is a biologic treatment used for moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. It works by targeting and inhibiting interleukin-23 (IL-23), a protein that plays a key role in the inflammatory processes associated with these conditions. Tremfya is given through a subcutaneous injection, typically once every 8 weeks after an initial loading dose.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Tremfya include moderate-to-severe plaque psoriasis and active psoriatic arthritis (PSA). Moderate-to-severe plaque psoriasis is a chronic condition marked by red, inflamed skin patches covered in silvery scales. Tremfya is available in several formulations, including subcutaneous injection and intravenous infusion, and is distributed through hospital and retail pharmacies. It is prescribed to a wide range of patients, including adults and the elderly.

The tremfya market consists of sales of subcutaneous injection pens, pre-filled syringes, and vials for healthcare providers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.